X-CELL MEDICAL COMPLETES ENROLLMENT FOR CLINICAL TRIAL OF ETHOS II ESTRADIOL ELUTING STENT
X-Cell Medical, Inc. announced May 16 that the Company has completed enrollment in its ETHOS II multinational clinical trial to study the
safety and effectiveness of the ETHOS Coronary Stent System. ETHOS II drug eluting stents (DES) are coated with a second generation formulation of 17(beta)-estradiol, an approved drug used in hormone replacement therapy and other indications, and are specifically designed to enhance safety through substantially reduced polymer load and estradiol dose.
Genetic Engineering News